31AA Extensive Human
Semaglutide
Long-acting GLP-1 receptor agonist driving clinically significant weight loss and cardiovascular risk reduction through appetite suppression and glucose-dependent insulin stimulation.
In Plain English: Semaglutide is a man-made version of a natural gut hormone called GLP-1 that your body releases after eating. It tells your pancreas to release more insulin when blood sugar is high, signals your brain to reduce hunger, and slows how quickly food leaves your stomach — together producing meaningful weight loss and better blood sugar control.
Research Maturity
Extensive Human (5,000+ published papers since 2012; multiple Phase III RCTs+ Studies)
Quick Facts
Focus
Glycemic Control
Metabolic Health
Weight Management
Route
Oral
SubQ
Origin
Synthetic analog of human GLP-1, engineered by Novo Nordisk. The native hormone is secreted by L-cells in the small intestine; semaglutide replicates its structure at 94% homology with modifications to extend half-life. FDA approved: 2017 (Ozempic, T2D); 2021 (Wegovy, obesity).
Mechanism
Selectively binds GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion and suppressing glucagon. Aib at position 2 blocks DPP-4 cleavage; C18 fatty diacid at Lys26 enables albumin binding, extending half-life to ~168 hours. CNS GLP-1R activation suppresses appetite.
Outcome
HbA1c reduction, body weight percentage change, MACE incidence, fasting plasma glucose, waist circumference, systolic blood pressure, LDL-C, hepatic fat fraction (NAFLD/NASH), and kidney function markers.
Safety Flags & Warnings
Thyroid C-Cell Tumour Risk (Black Box)
GI Adverse Events (Nausea, Vomiting)
Acute Pancreatitis Signal
Gallbladder Disease
NAION / Vision Loss Risk
Muscle Mass Loss
Pregnancy Contraindication
Always consult a licensed physician. Research purposes only.
€18 / mg
